Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

24Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.

Cite

CITATION STYLE

APA

Chen, M., Hu, S., Li, Y., Jiang, T. T., Jin, H., & Feng, L. (2020, December 1). Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. Signal Transduction and Targeted Therapy. Springer Nature. https://doi.org/10.1038/s41392-020-00347-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free